CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (448)	12/8/1999 9:27:00 PM
From: tnsaf	Read Replies (1) of 666

I don't recall any mention of the October 1999 "Current Opinion in Immunology" which has an article titled "A new era for radiolabeled antibodies in cancer?" Has an extensive reference list and mentions trials for several indications by several companies in the field. Especially interesting is NeoRx which was mentioned earlier on a thread by RWR. The article comments on the mechanism of the therapy, and says about a P1 trial that "dosimetry estimates indicated that, with the PretargetTM method, the ratios of radiation doses in the tumor (compared with the whole body) were 2-3 times higher than those achieved with anti-CD20 antibodies in conventional RIT." RIT=radioimmunotherapy. Trial results were CR=2/7 PR=2/7. Also mentioned is a different pretargeting approach. NERX and IMMU, which are mentioned in the article, had nice ASH pops. Note that the Current Opinion web site still has free access to articles for all their journals. Jason

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next